Table 3.

BsAbs bridge two receptors in clinical stages.

Classification	Target	Name	Indication	Phase	Clinical trial
Bridging two receptors on tumor cells	CD19 × CD47	TG-1801	B-cell lymphoma	Ⅰ	NCT03804996
	CD20 × CD47	IMM0306	B-NHL	Ⅰ	CTR20192612
	EGFR × cMET	EMB-01	Neoplasms	I/II	NCT05176665
	EGFR × HER3	Duligotuzumab	Head and neck cancer	Ⅰ	NCT01911598
	EGFR × MET	LY3164530	Neoplasms	Ⅰ	NCT02221882
	HER2 × HER2	Zanidatamab	HER2+/HR+ breast cancer	Ⅱ	NCT04224272
	HER2 × HER3	Zenocutuzumab	Solid tumours harboring NRG1 fusion	Ⅱ	NCT02912949
	HER3 × IGF-1R	MM-141	Pancreatic cancer	Ⅱ	NCT02538627
	LRP5 × LRP6	BI905677	Neoplasms	Ⅰ	NCT03604445
	PD-L1 × CD47	IBI322	Advanced malignant tumors lymphomas	Ⅰ	NCT04338659
Bridging two receptors on immune cells	CD40 × 4-1BB	GEN1042	Malignant solid tumor	Ⅰ/Ⅱ	NCT04083599
	CTLA-4 × LAG-3	Xmab22841	Melanoma	Ⅰ	NCT03849469
	CTLA-4 × OX40	ATOR-1015	Solid tumor	Ⅰ	NCT03782467
	OX40 × 4-1BB	FS120	Advanced cancer	Ⅰ	NCT04648202
	PD-1 × CTLA-4	AK104	Cervical cancer	Ⅱ	NCT05227651
	PD-1 × ICOS	Xmab23104	Selected advanced solid tumors	Ⅰ	NCT03752398
	PD-1 × LAG-3	Tebotelimab	Gastric cancer	Ⅱ/Ⅲ	NCT04082364
	PD-1 × TIM-3	RG7769	Solid tumors	Ⅰ	NCT03708328
Bridging receptors on tumor and immune cells	CD40 × MSLN	ABBV-428	Advanced solid tumors cancer	Ⅰ	NCT02955251
	HER2 × 4-1BB	PRS-343	HER2-positive solid tumors	Ⅰ	NCT03330561
	PD-1 × PD-L1	IBI318	Advanced cutaneous squamous cell carcinoma	Ⅰ/Ⅱ	NCT04611321
	PD-L1 × 4-1BB	MCLA-145	Advanced cancer	Ⅰ	NCT03922204
	PD-L1 × CTLA-4	KN046	Thymic carcinoma	Ⅱ	NCT04925947
	PD-L1 × LAG-3	FS118	Advanced cancer	Ⅰ/Ⅱ	NCT03440437
	PD-L1 × TIM-3	LY3415244	Solid tumor	Ⅰ	NCT03752177
	PSMA × CD28	REGN5678	Metastatic castration-resistant prostate cancer	Ⅰ/Ⅱ	NCT03972657